Figure 5

Treatment of SCC13 cells with GSPs reverses epithelial-to-mesenchymal transition. (A) Treatment of SCC13 cells with GSPs for 12 h resulted in loss of mesenchymal structure or morphology of cells. Cells lost their spindle shape morphology. Inset pictures showed magnified cell structure. (B) Treatment of cells with GSPs enhances the levels of E-cadherin, an epithelial biomarker, in the cells dose-dependently. (C) Treatment of cells with GSPs decreases the levels of mesenchymal biomarkers in SCC13 cells, such as N-cadherin, vimentin and fibronectin, in a dose-dependent manner. (D) Treatment of SCC13 cells with erlotinib, an inhibitor of EGFR, for 12 h decreases the levels of mesenchymal biomarkers, such as N-cadherin, vimentin and fibronectin.